Terms: = Lung cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
471 results:
1. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
[TBL] [Abstract] [Full Text] [Related]
2. il-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept.
Roser LA; Sakellariou C; Lindstedt M; Neuhaus V; Dehmel S; Sommer C; Raasch M; Flandre T; Roesener S; Hewitt P; Parnham MJ; Sewald K; Schiffmann S
J Immunotoxicol; 2024 Dec; 21(1):2332177. PubMed ID: 38578203
[TBL] [Abstract] [Full Text] [Related]
3. CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
Na K; Lee S; Kim DK; Kim YS; Hwang JY; Kang SS; Baek S; Lee CY; Yang SM; Han YJ; Kim MH; Han H; Kim Y; Kim JH; Jeon S; Byeon Y; Lee JB; Lim SM; Hong MH; Pyo KH; Cho BC
Front Immunol; 2024; 15():1336246. PubMed ID: 38515751
[TBL] [Abstract] [Full Text] [Related]
4. Antiproliferative and immunomodulative potential of Citrullus colocynthis and its bioactive compounds in human lymphocytes and lung cells.
Stein C; Voigts J; Niederreiter L; Kowarschik S; Huber R; Lüth VM
J Ethnopharmacol; 2024 Jun; 328():118053. PubMed ID: 38499257
[TBL] [Abstract] [Full Text] [Related]
5. Mathematical modeling and control of lung cancer with il2 cytokine and anti-PD-L1 inhibitor effects for low immune individuals.
Ahmad A; Kulachi MO; Farman M; Junjua MU; Bilal Riaz M; Riaz S
PLoS One; 2024; 19(3):e0299560. PubMed ID: 38483931
[TBL] [Abstract] [Full Text] [Related]
6. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
7. Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.
Borgers JSW; van Schijndel AW; van Thienen JV; Klobuch S; Seijkens TTP; Tobin RP; van Heerebeek L; Driessen-Waaijer A; Rohaan MW; Haanen JBAG
ESMO Open; 2024 Feb; 9(2):102383. PubMed ID: 38364453
[TBL] [Abstract] [Full Text] [Related]
8. Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer.
Sundström P; Dutta N; Rodin W; Hallqvist A; Raghavan S; Quiding Järbrink M
Oncoimmunology; 2024; 13(1):2312631. PubMed ID: 38343750
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy against lung cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.
Toyofuku T; Ishikawa T; Nojima S; Kumanogoh A
J Immunol; 2024 Mar; 212(5):917-927. PubMed ID: 38214607
[TBL] [Abstract] [Full Text] [Related]
11. Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma.
Yu T; Nie FQ; Zhang Q; Yu SK; Zhang ML; Wang Q; Wang EX; Lu KH; Sun M
Cell Death Dis; 2024 Jan; 15(1):12. PubMed ID: 38182561
[TBL] [Abstract] [Full Text] [Related]
12. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
[TBL] [Abstract] [Full Text] [Related]
13. Association of white matter hyperintensities with long-term EGFR-TKI treatment and prediction of progression risk.
Yang H; Meng R; Jiang J; Luo Y; Deng X; Yang S; Chen S; Wu J; Wan Y; Li Y; Jin H; He Q; Wang D; Chang J; Yang K; Zhou Y; Hu B
Brain Behav; 2023 Dec; 13(12):e3326. PubMed ID: 38054663
[TBL] [Abstract] [Full Text] [Related]
14. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy.
Leung EL; Li RZ; Fan XX; Wang LY; Wang Y; Jiang Z; Huang J; Pan HD; Fan Y; Xu H; Wang F; Rui H; Wong P; Sumatoh H; Fehlings M; Nardin A; Gavine P; Zhou L; Cao Y; Liu L
Nat Commun; 2023 Aug; 14(1):5115. PubMed ID: 37607911
[TBL] [Abstract] [Full Text] [Related]
15. Effective intravenous delivery of adenovirus armed with TNFα and il-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Kudling TV; Clubb JHA; Pakola S; Quixabeira DCA; Lähdeniemi IAK; Heiniö C; Arias V; Havunen R; Cervera-Carrascon V; Santos JM; Sutinen E; Räsänen J; Borenius K; Mäyränpää MI; Aaltonen E; Sorsa S; Hemminki O; Kanerva A; Verschuren EW; Ilonen I; Hemminki A
Oncoimmunology; 2023; 12(1):2241710. PubMed ID: 37546696
[TBL] [Abstract] [Full Text] [Related]
16. Bakuchiol inhibits lung cancer by modulating tumor microenvironment and the expression of PD-L1.
Lin M; Xu Q; Luo Y; Liu G; Hou P
J Biochem Mol Toxicol; 2023 Sep; 37(9):e23401. PubMed ID: 37338089
[TBL] [Abstract] [Full Text] [Related]
17. Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels.
Zhao N; Jiang A; Shang X; Zhao F; Wang R; Fu X; Ruan Z; Liang X; Tian T; Yao Y; Li C
J Immunother; 2023 Oct; 46(8):310-322. PubMed ID: 37335173
[TBL] [Abstract] [Full Text] [Related]
18. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.
Donnenberg VS; Luketich JD; Sultan I; Lister J; Bartlett DL; Ghosh S; Donnenberg AD
Front Immunol; 2023; 14():1157697. PubMed ID: 37063842
[TBL] [Abstract] [Full Text] [Related]
19. Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.
Tozuka T; Yanagitani N; Yoshida H; Manabe R; Ogusu S; Tsugitomi R; Sakamoto H; Amino Y; Ariyasu R; Uchibori K; Kitazono S; Seike M; Gemma A; Nishio M
Invest New Drugs; 2023 Jun; 41(3):411-420. PubMed ID: 37058183
[TBL] [Abstract] [Full Text] [Related]
20. Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer.
Monkman J; Kim H; Mayer A; Mehdi A; Matigian N; Cumberbatch M; Bhagat M; Ladwa R; Mueller SN; Adams MN; O'Byrne K; Kulasinghe A
Immunology; 2023 Aug; 169(4):487-502. PubMed ID: 37022147
[TBL] [Abstract] [Full Text] [Related]
[Next]
